header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

78 – LATERAL FEMORAL CUTANEOUS NERVE (LFCN) NEUROPRAXIA AFTER ANTERIOR APPROACH TOTAL HIP ARTHROPLASTY



Abstract

Purpose: LFCN neuropraxia is a known complication of the anterior approach to the hip joint. The objective of this study was to define the incidence, functional impact and natural history of this neuropraxia in the anterior approach after both hip resurfacing (HR) and primary total hip arthroplasty (THA).

Method: Between September 2006 and January 2008, 132 consecutive patients underwent a direct anterior hip approach (DAA) (55 THR; 77 HR). Sixty-two patients were female and 70 were male; the mean age was 55.54 (range, 29.9 to 88.7). Self reported questionnaires for sensory deficits of LFCN, a neuropathic pain score (DN4) as well as SF-12, UCLA and WOMAC scores were completed. A subset of 60 patients (30 THA, 30 resurfacing) was evaluated at two time intervals (6 and 12 months).

Results: One hundred and seven patients (81%) reported LFCN neuropraxia, with a mean severity score of 2.32/10 (SD, 2.11); mean DN4 score of 2.42/10 (SD, 2.37). Hip resurfacing had a higher incidence of neuro-praxia compared to THA: 91% versus 67% (p=0.02), respectively. No functional limitations were reported on SF-12, WOMAC or UCLA scores. Of the subset of 60 patients, 53 (88.3%) reported neuropraxia at the six month follow-up interval with only three (5.7%) having complete resolution at 12 months. Patients who reported neuropraxia at both testing intervals did report an improvement in DN4 scores: 3.6 versus 2.5 at 6 and 12 months, respectively (p=0.02).

Conclusion: Although LFCN neuropraxia is a frequent complication after DAA total hip arthroplasty, it does not lead to any functional limitations. A decrease in symptoms does occur over time, with only a small number of patients reporting complete resolution.

Correspondence should be addressed to: COA, 4150 Ste. Catherine St. West Suite 360, Westmount, QC H3Z 2Y5, Canada. Email: meetings@canorth.org